The impact of enrollment in clinical trials on survival of patients with glioblastoma

Journal of Clinical Neuroscience

Volumn 19, Issue 11, 2012, Pages 1530-1534

  Shahar, Tal ^a   Nossek, Erez ^a   Steinberg, David M ^b   Rozovski, Uri ^a   Blumenthal, Deborah T ^a   Bokstein, Felix ^a   Sitt, Razi ^a   Freedman, Sigal ^a   Corn, Benjamin W ^a   Kanner, Andrew A ^a   Ram, Zvi ^a  

^a TEL AVIV SOURASKY MEDICAL CENTER   (Israel)

^b TEL AVIV UNIVERSITY   (Israel)

Author keywords

Clinical trials; Glioblastoma; Neuro oncology; Neurosurgery; Survival analysis

Indexed keywords

BEVACIZUMAB; CARBOPLATIN; CARMUSTINE; GLIADEL WAFER; LOMUSTINE; POLIFEPROSAN; PROCARBAZINE; TEMOZOLOMIDE; UNCLASSIFIED DRUG; VINCRISTINE;

AGE; ARTICLE; CANCER PROGNOSIS; CANCER RADIOTHERAPY; CANCER SURGERY; CLINICAL TRIAL (TOPIC); GLIOBLASTOMA; HUMAN; KARNOFSKY PERFORMANCE STATUS; OVERALL SURVIVAL; PATIENT PARTICIPATION; PREDICTIVE VALUE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); RETROSPECTIVE STUDY; SURVIVAL; SURVIVAL PREDICTION; SURVIVAL TIME;

AGED; BRAIN NEOPLASMS; CASE MANAGEMENT; CLINICAL TRIALS AS TOPIC; FEMALE; GLIOBLASTOMA; HUMANS; KAPLAN-MEIER ESTIMATE; KARNOFSKY PERFORMANCE STATUS; MAGNETIC RESONANCE IMAGING; MALE; MIDDLE AGED; REGRESSION ANALYSIS; RETROSPECTIVE STUDIES; SURVIVAL ANALYSIS; TREATMENT OUTCOME;

EID: 84867101729     PISSN: 09675868     EISSN: 15322653     Source Type: Journal    
DOI: 10.1016/j.jocn.2012.04.005     Document Type: Article

References (32)

1. L.M. DeAngelis Brain tumors N Engl J Med 344 2001 114 123
2. R. Stupp, W.P. Mason, and M.J. van den Bent Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma N Engl J Med 352 2005 987 996
3. H. Gilbert, A.R. Kagan, and F. Cassidy Glioblastoma multiforme is not a uniform disease! Cancer Clin Trials 4 1981 87 89
4. W.J. Curran Jr., C.B. Scott, and J. Horton Recursive partitioning analysis of prognostic factors in three Radiation Therapy Oncology Group malignant glioma trials J Natl Cancer Inst 85 1993 704 710
5. T. Homma, T. Fukushima, and S. Vaccarella Correlation among pathology, genotype, and patient outcomes in glioblastoma J Neuropathol Exp Neurol 65 2006 846 854
6. M. Weller, J. Felsberg, and C. Hartmann Molecular predictors of progression-free and overall survival in patients with newly diagnosed glioblastoma: a prospective translational study of the German Glioma Network J Clin Oncol 27 2009 5743 5750
7. J.F. Mineo, I. Quintin-Roue, and B. Lucas Glioblastomas: clinical study and search for prognostic factors Neurochirurgie 48 2002 500 509
8. K.R. Lamborn, S.M. Chang, and M.D. Prados Prognostic factors for survival of patients with glioblastoma: recursive partitioning analysis Neuro-oncol 6 2004 227 235
9. N. Sanai, and M.S. Berger Glioma extent of resection and its impact on patient outcome Neurosurgery 62 2008 753 764 [discussion 264-6]
10. J.F. Mineo, A. Bordron, and M. Baroncini Prognosis factors of survival time in patients with glioblastoma multiforme: a multivariate analysis of 340 patients Acta Neurochir (Wien) 149 2007 245 252 [discussion 52-3]
11. N.G. Rainov A phase III clinical evaluation of herpes simplex virus type 1 thymidine kinase and ganciclovir gene therapy as an adjuvant to surgical resection and radiation in adults with previously untreated glioblastoma multiforme Hum Gene Ther 11 2000 2389 2401
12. S. Kunwar, M.D. Prados, and S.M. Chang Direct intracerebral delivery of cintredekin besudotox (IL13-PE38QQR) in recurrent malignant glioma: a report by the Cintredekin Besudotox Intraparenchymal Study Group J Clin Oncol 25 2007 837 844
13. J.K. Raty, J.T. Pikkarainen, and T. Wirth Gene therapy: the first approved gene-based medicines, molecular mechanisms and clinical indications Curr Mol Pharmacol 1 2008 13 23
14. M. Westphal, D.C. Hilt, and E. Bortey A phase 3 trial of local chemotherapy with biodegradable carmustine (BCNU) wafers (Gliadel wafers) in patients with primary malignant glioma Neuro-oncol 5 2003 79 88
15. Z. Lidar, Y. Mardor, and T. Jonas Convection-enhanced delivery of paclitaxel for the treatment of recurrent malignant glioma: a phase I/II clinical study J Neurosurg 100 2004 472 479
16. Comparison of TransMID vs standard treatment of cancerous brain tumors; 2004. Available from: http://clinicaltrials.gov/ct2/show/NCT00088400.
17. E.D. Kirson, R.S. Schneiderman, and V. Dbaly Chemotherapeutic treatment efficacy and sensitivity are increased by adjuvant alternating electric fields (TTFields) BMC Med Phys 9 2009 1
18. RTOG®0525. Phase III trial comparing conventional adjuvant temozolomide with dose intensive temozolomide in patients with newly diagnosed glioblastoma. The Radiation Therapy Oncology Group®. Available from: http://www.rtog.org/ClinicalTrials/ProtocolTable/StudyDetails.aspx?study=0525.
19. RTOG®0625. A randomized phase II trial of bevacizumab with irinotecan or bevacizumab with temozolomide in recurrent glioblastoma. The Radiation Therapy Oncology Group®. Available from: http://www.rtog.org/ClinicalTrials/ ProtocolTable/StudyDetails.aspx?study=0625.
20. R Development Core Team. R: a language and environment for statistical computing [program]. Vienna, Austria; 2009.
21. Therneau TM, Atkinson EJ. An introduction to recursive partitioning using the RPART Routines Technical Report Series No. 61. Rochester, MN: Section of Biostatistics, Mayo Clinic; 1997.
22. G.E. Vist, D. Bryant, and L. Somerville Outcomes of patients who participate in randomized controlled trials compared to similar patients receiving similar interventions who do not participate Cochrane Database Syst Rev 3 2008 MR000009
23. J.M. Peppercorn, J.C. Weeks, and E.F. Cook Comparison of outcomes in cancer patients treated within and outside clinical trials: conceptual framework and structured review Lancet 363 2004 263 270
24. ECRI. Should I enter a clinical trial? A patient reference guide for adults with a serious or life-threatening illness. A Report by ECRI Commissioned by AAHP; 2002.
25. D.A. Braunholtz, S.J. Edwards, and R.J. Lilford Are randomized clinical trials good for us (in the short term)? Evidence for a "trial effect" J Clin Epidemiol 54 2001 217 224
26. C.A. Stiller Centralised treatment, entry to trials and survival Br J Cancer 70 1994 352 362
27. K. Antman, D. Amato, and W. Wood Selection bias in clinical trials J Clin Oncol 3 1985 1142 1147
28. Z.U. Rahman, D.K. Frye, and A.U. Buzdar Impact of selection process on response rate and long-term survival of potential high-dose chemotherapy candidates treated with standard-dose doxorubicin-containing chemotherapy in patients with metastatic breast cancer J Clin Oncol 15 1997 3171 3177
29. V.H. Murthy, H.M. Krumholz, and C.P. Gross Participation in cancer clinical trials: race-, sex-, and age-based disparities JAMA 291 2004 2720 2726
30. W.B. Sateren, E.L. Trimble, and J. Abrams How sociodemographics, presence of oncology specialists, and hospital cancer programs affect accrual to cancer treatment trials J Clin Oncol 20 2002 2109 2117
31. B.E. Hillner, T.J. Smith, and C.E. Desch Hospital and physician volume or specialization and outcomes in cancer treatment: importance in quality of cancer care J Clin Oncol 18 2000 2327 2340
32. M. Kogevinas, M.G. Marmot, and A.J. Fox Socioeconomic differences in cancer survival J Epidemiol Community Health 45 1991 216 219